Bicara Therapeutics (BCAX) Accumulated Expenses (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Accumulated Expenses of $1.3 million for Q1 2026, down 59.38% year-over-year from $3.2 million in Q1 2025, and down 89.17% quarter-over-quarter from $12.0 million in Q2 2025.
Bicara Therapeutics (BCAX) Accumulated Expenses (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Accumulated Expenses history runs 4 years deep, the most recent figure standing at $1.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 59.38% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at $1.3 million (down 59.38% YoY), while the FY2023 annual figure was $8.1 million, changed N/A from the prior year.
- Accumulated Expenses for Q1 2026 stood at $1.3 million, down from $12.0 million in the prior quarter.
- The five-year high for Accumulated Expenses was $12.0 million in Q2 2025, with the low at $1.3 million in Q1 2026.
- The 4-year median for Accumulated Expenses is $3.2 million (2025), against an average of $5.4 million.
- Peak annual rise in Accumulated Expenses reached 59.38% in 2026, while the deepest fall reached 59.38% in 2026.
- Bicara Therapeutics' Accumulated Expenses stood at $8.1 million in 2023, then tumbled by 70.2% to $2.4 million in 2024, then soared by 400.0% to $12.0 million in 2025, then slumped by 89.17% to $1.3 million in 2026.
- Business Quant data shows BCAX's Accumulated Expenses at $1.3 million in Q1 2026, $12.0 million in Q2 2025, and $3.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.67 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Jun 30, 2025 | 12.00 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Sep 30, 2024 | 2.40 Mn |
| Dec 31, 2023 | 8.05 Mn |